As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

Sanofi will receive about €10 billion ... A or B regardless of inhibitors and additional approvals for Dupixent in COPD in Japan and CSU in the U.S. and Sarclisa across different lines in ...

Itepekimab: expanding clinical studies beyond COPD into chronic rhinosinusitis ... About itepekimabIn partnership with Regeneron, Sanofi is exploring itepekimab, a fully human monoclonal antibody ...

phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase ...